Renal neoplasms in tuberous sclerosis mice are neurocristopathies

Highlights
- Renal and hepatic tumors in Tsc2+/- mice comprise of neural crest cells (NCCs)
- NCC proliferation increased with Tsc2+/- mice tumor volume and multiplicity
- Multipotent Tsc2+/- NCCs induce tumors in ectodermally derived and non-neural tissues
- Pharmacologically targeting NCCs offers an alternate treatment for tuberous sclerosis

Unachukwu et al., iScience 24, 102684
July 23, 2021 © 2021 The Authors.
https://doi.org/10.1016/j.isci.2021.102684

https://iScience.celpress.com/doi/10.1016/j.isci.2021.102684

Created with BioRender.com
Renal neoplasms in tuberous sclerosis mice are neurocristopathies

Uchenna Unachukwu,1 Takayuki Shiomi,2 Monica Goldklang,1 Kiran Chada,3 and Jeanine D’Armiento1,4,*

SUMMARY
Tuberous sclerosis (TS) is characterized by highly variable benign neoplasms and hamartomatous lesions in the brain, skin, heart, lungs, and kidneys (Dabora et al., 2001), seizures, and TS-associated neuropsychiatric disorders (de Vries et al., 2015). Heterozygous mutations of the tuberous sclerosis genes TSC1 or TSC2 have been causatively linked to the abnormal cytological proliferation characterizing tumors in patients with TS (Cansillo et al., 2000; Giannikou et al., 2016; Jones et al., 1999; Sato et al., 2002; Smolarek et al., 1998; Yu and Henske, 2010); however, not all tumors exhibit mutations in these genes (Sanchez et al., 2005; Tyburczy et al., 2013). These TSC1/2 mutations lead to hyperactivation of the mechanistic target of rapamycin (mTOR) pathway in a subset of the tumors (Clements et al., 2015; Goncharova et al., 2005; Tyburczy et al., 2015). These TSC1/2 mutations lead to hyperactivation of the mechanistic target of rapamycin (mTOR) pathway in a subset of the tumors (Clements et al., 2015; Goncharova et al., 2005; Tyburczy et al., 2015). These TSC1/2 mutations lead to hyperactivation of the mechanistic target of rapamycin (mTOR) pathway in a subset of the tumors (Clements et al., 2015; Goncharova et al., 2005; Tyburczy et al., 2015).

INTRODUCTION
Tuberous sclerosis (TS) is characterized by highly variable benign neoplasms and hamartomatous lesions in the brain, skin, heart, lungs, and kidneys (Dabora et al., 2001), seizures, and TS-associated neuropsychiatric disorders (de Vries et al., 2015). Heterozygous mutations of the tuberous sclerosis genes TSC1 or TSC2 have been causatively linked to the abnormal cytological proliferation characterizing tumors in patients with TS (Cansillo et al., 2000; Giannikou et al., 2016; Jones et al., 1999; Sato et al., 2002; Smolarek et al., 1998; Yu and Henske, 2010); however, not all tumors exhibit mutations in these genes (Sanchez et al., 2005; Tyburczy et al., 2013). These TSC1/2 mutations lead to hyperactivation of the mechanistic target of rapamycin (mTOR) pathway in a subset of the tumors (Clements et al., 2015; Goncharova et al., 2005; Tyburczy et al., 2015). These TSC1/2 mutations lead to hyperactivation of the mechanistic target of rapamycin (mTOR) pathway in a subset of the tumors (Clements et al., 2015; Goncharova et al., 2005; Tyburczy et al., 2015).

Histologically, TS neoplasms commonly comprise immature cells exhibiting either neuronal characteristic, as found in cortical tubers, subependymal giant-cell astrocytomas, and retinal astrocytic hamartomas, and non-neuronal phenotypes found mostly outside of central nervous system (CNS) organs (Brigo et al., 2018; Delaney et al., 2014; Feliciano, 2020). While evidence supporting the postulate that CNS lesions originate due to mTOR-induced neural dysplasia, hyperexcitability, abnormal differentiation, and defective maturation of neural progenitor cells during embryonic development is quite compelling (Feliciano et al., 2012; Lin et al., 2016; Park et al., 2018), the ontogenetic mechanisms of non-CNS lesions of TS is...
not well understood. For instance, some research groups have recently made strides to identify the potential origin of the TS neoplastic cells outside the CNS albeit non-concordant findings, including the hypotheses that lymphangioleiomyomatosis (LAM), the main pulmonary manifestation of TS, is caused by cells of a pleural mesothelial origin (Clements et al., 2020) or uterine origin (Guo et al., 2020). Similarly, postulates of a neural crest origin for renal angiomyolipomas (AMLs), the most common cause of mortality in adult TS (Lam et al., 2018), and patients with LAM have been proposed by others. These investigators have observed that lesions in LAM and renal AMLs comprise heterogeneous cells that consistently express markers of smooth muscle cells (α-SMA, vimentin, and desmin), melanocytes (HMB45, MART-1), and adipocytes (AdPLA2) (Taveira-DaSilva and Moss, 2015), cell types that are phenotypically mesenchymal and in most cases foreign to their host tissue interstitium (Henske and McCormack, 2012). Coupled with the multi-organ occurrence of TS lesions (Delaney et al., 2014; Henske and McCormack, 2012), the pathogenesis of LAM and non-CNS lesions in TS seems reminiscent of developmental paradigms of neural crest lineages that give rise to portions of the embryonic mesenchyme either as trunk neural crest cells (TNCCs), cranial neural crest cells (CNCC), and cardiac or vagal neural crest cells (NCCs) (Baggiolini et al., 2015). These neural crest subtypes are postulated to determine TS disease heterogeneity (Delaney et al., 2014; Henske and McCormack, 2012), and the timing of Tsc1/2 mutations in these cells during embryogenesis is predicted to govern the severity of the TS and LAM phenotype (Delaney et al., 2014). However, no experimental data exist to support the hypothesis which remains to be directly and comprehensively investigated (Delaney et al., 2014). Cumulatively, these studies do suggest that TS neoplasms have an embryonic origin.

Given the relatively high frequency of renal lesions in TS, TS-associated lymphangioleiomyomatosis (TS-LAM), and sporadic LAM (S-LAM) (Dixon et al., 2011; Rakowski et al., 2006; Siroky et al., 2011), we employed a tuberous sclerosis Tsc2<sup>-/-</sup> reporter mouse model that spontaneously develops renal cystadenomas (Onda et al., 1999) to test the hypothesis that mouse renal neoplasms are neurocristopathies, pathologies borne of a neural crest lineage. The expression of the tdTomato (TdT) reporter gene in these mice is governed by a Cre-recombinase-driven event under the control of the myelin protein zero (Mpz) promoter, a neural crest lineage marker (Yamauchi et al., 1999). This enables tissues derived from the neural crest to be detected in mice and pathogenic cells of neural crest lineage to be determined and tracked in growing tumors of the tuberous sclerosis mice and in postmortem biochemical analyses. Mpz expression has previously been associated with multipotent post-migratory differentiating neural crest progenitors that exhibit fate restrictions including smooth muscle-like cells, glia, and neurons dependent on the cellular context and instructive environmental cues (Dupin and Coelho-Aguiar, 2013; Hagedorn et al., 1999). HMB45-positive angiomylipoma and cystic single cells have also been identified in otherwise normal renal parenchyma (Siroky et al., 2011) reminiscent of migratory pathogenic neural crest-derived cells that defines our hypothesis (Pacheco-Rodriguez and Moss, 2010). The slow development of these tumors in the heterozygote Tsc2 mice (Kwiatkowski, 2010; Onda et al., 1999) mimics the gradual benign growth pattern of TS hamartomas in most patients making this mouse model a suitable translational animal model for this study.

Using a non-invasive imaging strategy comprising epifluorescent IVIS spectral imaging and small animal ultrasound, we report the earliest detection of ectopic renal neoplasms in these tuberous sclerosis mice at 4 months of age. We resolved that a small population of primitive neural crest precursors, whose number increases with increasing tumor volume and maturity, populates renal tumors in the tuberous sclerosis mice and could source renal tumor ontogenesis in TS.

**RESULTS**

**Generation of the tuberous sclerosis reporter mouse model**

To determine whether TS tumor cells originate from a neural crest lineage, we generated a recapitulatory mouse model by crossing floxed B6.Cg-Gt(Rosa)26Sor<sup>tm1(CAG-tdTomato)Hze</sup>/J reporter mice with transgenic B6N.FVB-Tg(Mpz-Cre)26Mes/J mice. Using genotyping studies, we next selected Mpz(Cre)/Tdt<sup>fl/fl</sup> reporter mice progeny driven by the myelin protein zero promoter (Mpz) (Yamauchi et al., 1999). Upon breeding these mice with the Tsc2<sup>-/-</sup> tuberous sclerosis mice (Onda et al., 1999) and F1 hybrid crosses of resulting Tsc2<sup>-/-</sup>/Mpz(Cre)/Tdt<sup>fl/fl</sup> progeny, experimental mice denoting genotypes Tsc2<sup>-/-</sup>/Mpz(Cre)/Tdt<sup>fl/fl</sup>, Tsc2<sup>-/-</sup>/Mpz(Cre)/Tdt<sup>+,/+</sup>, Tsc2<sup>-/-</sup>/Mpz(Cre)/Tdt<sup>+,+</sup>, and wild-type control Tsc2<sup>-/-</sup>/Mpz(Cre)/Tdt<sup>+,+</sup> mice were aged for 16 months to allow for tumor development. A schematic of genetic crosses involved in the development of this mouse model is displayed in Figure 1A. These crossings generate an animal model that allows for systemic epifluorescent detection of neural crest lineage cells in developing TS.
tumors by Cre-recombinase-mediated insertion of the Mpz promoter to drive tdTomato expression (Liu et al., 2015; Yamauchi et al., 1999). Tumor tracking in this Tsc2+/C0 reporter mice was performed beginning at 2 months of age at biweekly intervals using sequential In Vivo Imaging System (IVIS) spectral imaging detecting tdTomato excitation/emission spectra at 570 nm/620 nm and small animal ultrasound. Small animal magnetic resonance imaging was used to confirm sites of tumor development prior to excision for subsequent analysis. Figure 1B displays results of IVIS spectral imaging of an array of 16-month-old littermate progeny of the selected genotypes used in this study showing tdTomato epifluorescence to be perceptibly brightest in the abdominal region of only the Tsc2+/C0/Mpz(Cre)/TdTfl/fl mice. Spectral quantification of tdTomato epifluorescence revealed significantly higher average radiant efficiency measurements (p < 0.0001****) in Tsc2+/C0/Mpz(Cre)/TdTfl/fl mice compared to other mouse genotypes in two different sets of mice imaging studies (Figure 1C). TS tumorigenesis in this select mouse group was further verified by ultrasound imaging resolving regions representing multiple peripheral tumors in the kidneys of Tsc2+/C0/Mpz(Cre)/TdTfl/fl mice (Figure D2) compared to tumor-less renal tissue in the Tsc2+/C0/Mpz(Cre)/TdTfl/fl mice (Figure D1). High-resolution magnetic resonance imaging confirmed the presence of bilateral cortical tumor growth in both kidneys of the Tsc2+/C0/Mpz(Cre)/TdTfl/fl mice (Figure 1E). Tsc2+/C0/Mpz(Cre)/TdTfl/fl mice spontaneously developed renal tumors which could not be detected by tdTomato epifluorescence. Hepatic lesions were also detected in the 16-month-old Tsc2+/C0/Mpz(Cre)/TdTfl/fl mice by ultrasound imaging (Figure S1B) compared to cross-sectional images of non-tumorigenic hepatic tissues recovered from Tsc2+/C0/Mpz(Cre)/TdTfl/fl mice (Figure S1A). The presence of hepatic lesions in the Tsc2+/C0/Mpz(Cre)/TdTfl/fl mice was further confirmed by high-resolution MRI (Figure S1C).

Renal tumorigenesis in Tsc2+/- mice correlates with onset and proliferation of neural crest precursor populations

Prior to our study, the earliest reported detection of renal neoplasms in tuberous sclerosis Tsc2+/- mouse models was at 6 months of age (Kobayashi et al., 1999; Kwiatkowski, 2010; Lam et al., 2018; Onda et al., 2018).
and earlier polycystic lesions occurring in the Dermo1Cre; Tsc2fl/fl mice led to mouse lethality by 3 weeks of age (Ren et al., 2016). We report the earliest detection of ectopic fluid-filled renal cysts spontaneously developing in the Tsc2+/−Mpz(Cre)TdTfl/fl mice at 4 months of age (Figure 2A), then pictured at 6 months (B), 12 months (C), and 16 months (D).

(E) Tumor volume increased from $4.68 \pm 1.5 \text{ mm}^3$ at 4 months of age (male/female, $N = 5$ animals) to $9.66 \pm 1.9 \text{ mm}^3$ at 6 months (male/female, $N = 6$ animals), to $56.8 \pm 16.0 \text{ mm}^3$ at 12 months (male/female, $N = 5$ animals), and then increasing by over $1,100\%$ to $645 \pm 202 \text{ mm}^3$ by 16 months of age (male/female, $N = 6$ animals).

(F–H) (F) The average number of tumors per mice increased proportionally during the same period from $1.50 \pm 0.3$ (male/female, $N = 5$ animals; $p = 0.895$) in 4-month-old mice, to $4.80 \pm 2.6$ (male/female, $N = 6$ animals) in 6-month-old mice, and $7.50 \pm 0.7$ (male/female, $N = 5$ animals; $p = 0.068$) in 12-month-old mice, reaching statistical significance in 16-month-old mice (8.40 ± 3.4 tumors; male/female, $N = 6$ animals) compared to the 2-month-old mice. Representative images of hematoxylin/eosin (H/E)-stained immunohistochemical slides of renal tissue cross sections (4μM thickness) from 12-month-old Tsc2+/−/Mpz(Cre)/TdTfl/fl mice (G) and Tsc2+/−/Mpz(Cre)/TdTfl/fl mice (H).

(I) Renal tumors from 4- to 16-month-old Tsc2+/−/Mpz(Cre)/TdTfl/fl mice were dissociated, gated for live/dead staining (Sytox Green(C)/DAPI(C)/DRAQ5(C)), and sorted for tdTomato expression in comparison with renal cortical cells obtained from age-matched Tsc2+/+Mpz(Cre)/TdTfl/fl mice.

1999), and earlier polycystic lesions occurring in the Dermo1Cre; Tsc2fl/fl mice led to mouse lethality by 3 weeks of age (Ren et al., 2016). We report the earliest detection of ectopic fluid-filled renal cysts spontaneously developing in the Tsc2+/−/Mpz(Cre)/TdTfl/fl mice at 4 months of age (Figure 2A). These tumors were detectable by both IVIS spectral imaging and ultrasound. By 6 months of age, multiple solid tumors and/or cysts containing denser fluid can be observed (Figure 2B), which increased in volume by 12 months (Figure 2C), and by 16 months, enlarged, dysmorphic, inflamed renal tissue coalescing with multiple cysts could be observed (Figure 2D). Individual renal tumor volumes varied widely within the same kidney and mice at all ages, doubling in the mean volume from $4.68 \pm 1.5 \text{ mm}^3$ at 4 months of age (male/female, $N = 4$ mice) to $9.66 \pm 1.9 \text{ mm}^3$ at 6 months (male/female, $N = 5$ mice), to $56.8 \pm 16.0 \text{ mm}^3$ at 12 months (male/female, $N = 3$ mice), and then increasing by over $1,100\%$ to $645 \pm 202 \text{ mm}^3$ by 16 months of age (Figure 2E). The average number of renal tumors per mice increased from $1.50 \pm 0.3$ (male/female, $N = 4$ mice; $p = 0.895$) in 4-month-old mice, to $4.80 \pm 2.6$ (male/female, $N = 5$ mice; $p = 0.213$) in 6-month-old mice, and to $7.50 \pm 0.7$ (male/female, $N = 3$ mice; $p = 0.068$) in 12-month-old mice, reaching statistical significance in 16-month-old mice (8.40 ± 3.4 tumors; male/female, $N = 5$ mice; $p = 0.025$) compared to the 2-month-old mice (Figure 2F).
Tsc2+/− mice renal tumors and comparative renal cortical tissues were excised at 4, 6, 12, and 16 months. Representative images of hematoxylin/eosin (H/E)-stained immunohistochemical slides of renal tissue cross sections (4 μm thickness) from 12-month-old Tsc2+/−/Mpz(Cre)/TdTfl/fl mice (Figure 2G) and Tsc2+/−/Mpz(Cre)/TdTfl/fl mice (Figure 2H) are depicted. Tsc2+/− reporter mice renal tissues and tumors were dissociated into single cell populations for flow cytometric sorting of tdTomato+ NCCs. Results indicate that the significant increase in renal tumor volume (Figure 2E) and number of tumors (Figure 2F) in Tsc2+/−/Mpz(Cre)/TdTfl/fl mice over the 16-month-period correlated with a marked increase in the fraction of gated tdTomato+ cells from an average of 0.60% beginning at 6 months, to 10.6% at 12 months, and 7.8% of the total number of sorted cells at 16 months (Figure 2I) compared to sorted cell fractions from Tsc2+/−/Mpz(Cre)/TdTfl/fl mice and Tsc2+/−/Mpz(Cre)/TdTfl/fl following gating protocols for live cells (DAPI(−)/Sytox Green(−)/DRAQ5(−)) and tdTomato+ expression. Representative dot plots comparing gating results of flow cytometric separation of renal tissue and tumor cells between Tsc2+/−/Mpz(Cre)/TdTfl/fl and Tsc2+/−/Mpz(Cre)/TdTfl/fl obtained at 4 months (Figures 3A and 3B), 6 months (Figures 3C and 3D), 12 months (Figures 3E and 3F), and 16 months (Figures 3G and 3H), respectively, are also displayed. Single cell suspensions of CNCCs (Figure 3I) and TNCCs (Figure 3J) excised from 9.5dpC Tsc2+/−Mpz(Cre)TdTfl/fl mouse embryos were used as positive controls to comparatively assess the emergence of tdTomato+ NCCs in tuberous sclerosis Tsc2+/− mice. The resolution of tdTomato+ cells in renal tumor cell dissociates indicates active Mpz promoter activity in cells of a neural crest lineage. This unique cell population likely results from migrants from the neural crest that retain their proliferative and stem cell character and differentiate into source pathogenic tumor cells of TS, as phenotypic manifestations of mono-allelic and biallelic mutations at the Tsc2 gene locus. Although the fraction of these tdTomato-expressing cells in both the renal and whole-cell populations analyzed by flow cytometry is quite low, they are proportional in quantity to the NCC precursors recoverable from 9.5dpC embryonic cranial tissue and mesodermal somite used as our cranial and trunk NCC controls, respectively (Figures 3I and 3J).

Characterization of neural crest lineage cells in Tsc2+/− mouse renal tumors

Immunohistochemical preparations of excised renal tumor slices (4 μm thickness) obtained from 6-month-old Tsc2+/−/Mpz(Cre)/TdTfl/fl mice revealed red fluorescent punctate cell masses occurring singly or in small colonies in the renal tumor slices following fluorescence excitation using the Texas Red chromatic filter (Figures 4A and 4B). The proportion of red fluorescent cells in renal tumors increased with age where even more colonies can be seen in the 12-month-old Tsc2+/−/Mpz(Cre)/TdTfl/fl mouse tumor slices (Figures 4C and 4D) and 16-month-old Tsc2+/−/Mpz(Cre)/TdTfl/fl mouse tumor slices (Figures 4F–4H) compared to renal tissue wildtype at the Tsc2 locus (Figure 4E). Double immunolabeling studies using the 16-month-old renal tumor slices reveal significant expression of neural crest marker CD57 (β-1,3-glucuroniltransferase (B3GAT1)) in select renal tumor cells by confocal microscopy, along with 4′,6-diamidino-2-phenylindole (DAPI) nuclear staining and endogenous tdTomato expression reporting the tumor’s neural crest phenotype (Figure 3H). These tdTomato+ cell masses were also observed in hepatic tumor slices obtained from Tsc2+/−/Mpz(Cre)/TdTfl/fl mice (Figures S1D and S1E). The myelin protein zero (Mpz)-driven tdTomato expression of cells in renal and hepatic tumors of the Tsc2+/− reporter mice is a direct demonstration of a neural crest lineage for these tumors. Although we have not yet successfully extracted sufficient reliable genomic and proteomic material from tdTomato+ flow-sorted cells for downstream applications in this pilot study, RT-qPCR analysis of excised whole renal tumors from Tsc2+/−/Mpz(Cre)/TdTfl/fl mice compared to age-matched Tsc2+/−/Mpz(Cre)/TdTfl/fl mouse renal tissue exhibited significantly higher expression of select neural crest markers Ap2a (p = 4.40 × 10−3**) and CD57 (p = 0.05*) (Figure 5A) in renal tumors assessed including Tsc2-null and Tsc2-expressing mouse renal tumors. In aggregate, Tsc2+/− mice renal tumors assessed in this study did not exhibit significantly different Tsc2 gene expression compared to renal cortical tissues in normal mice (p = 0.0824) (Figure 5B) in concordance with findings from our previous studies using this mouse model (D’Armiento et al., 2016).

DISCUSSION

The present study demonstrates through lineage tracing that renal angiomyolipomas and hepatic tumors in Tsc2+/− reporter mouse models harbor NCCs. The occurrence of this population of NCCs was confirmed using fluorescence and confocal microscopy, flow cytometric analyses, and immunohistochemistry, substantiating the lineage tracing results. The lineage tracing studies utilizing the myelin protein zero (Mpz) promoter, therefore, are representative of expression of the ectodermal neural crest. The immunologic expression of canonical neural crest marker CD57 in tdTomato-positive renal tumor cells (Figure 3H) further confirms their neural crest cellular identity, as well as the differential expression of multiple neural crest...
markers in diseased mouse renal tumors compared to healthy kidney tissues. The multipotency demonstrated by the expression pattern suggests that the tumor cell subpopulations are migrant neural crest progenitor relics of neurocristogenesis that have co-opted tumorigenesis in their various domiciled organs. Interestingly, the NCCs increased in number as the mice aged and the tumors increased in size. The described findings potentially allow for the development of efficacious targeted therapy for this untreated rare disease.

It is well established that neural crest progenitor cells are destined to delaminate from the neural tube, undergo epithelial-mesenchymal transitions (EMT), and invade multiple organs to give rise to CNCCs and trunk and vagal NCCs (Minarcik and Golden, 2003; Osumi-Yamashita et al., 1994; Serbedzija et al., 1992). NCCs are variably lineage restrictive in their multipotency, maintaining their ability to differentiate into few or many different cell types (Achilleos and Trainor, 2012; Baroffio et al., 1991; Calloni et al., 2009; Knispel et al., 2010; Motohashi et al., 2011), while retaining their multipotent self-renewal capacity even into adulthood in mammals (Bhatt et al., 2013). Interestingly, these cytogenetic activities mimic routine tumor cell physiology with ample evidence existing to demonstrate that cancer cells co-opt many of the genetic and molecular mechanisms used by developing NCCs including EMT, proliferation, migration, and differentiation (Maguire et al., 2015). Furthermore, the fate of these migratory and post-migratory NCCs is not completely determined, even after domiciliation in target organs, because they continue to generate multiple tissue derivatives (Maguire et al., 2015). The predilection of renal neoplasms in the Tsc2+/− mice and in most patients with TS could well be due to these embryogenetic lineage restrictions in the tumorigenic Tsc2+/− NCC subpopulations. Additionally, renal organs could also possess the most conducive microenvironment to co-opting tumorigenesis in these cells due to the presence of activating factors such as hormone stimulation (Yu et al., 2009).

The findings from the foregoing studies present a number of interesting possibilities. Given the embryonic nature of NCCs, it can be assumed that tumors in the tuberous sclerosis Tsc2+/− mouse model harbor NCCs possessing mono-allelic germine mutations at the Tsc2 gene loci. As haploinsufficient TS mutations have been shown to suffice for TS and LAM pathogenicity similar to Tsc2−/− neoplastic cells (D’Armino et al., 2016; Julian et al., 2017; Martin et al., 2017; Peri et al., 2017; Tam et al., 2019), multipotent Tsc2+/− NCCs could induce tumor development in both ectodermally-derived neural and non-neural tissues (Feliciano, 2020; Ferrans et al., 2000) located in multiple organs that are ontogenetic destinations for neural crest progenitor cells (Delaney et al., 2014). Supporting this postulate is the recent delineation of catabolic signaling potentially inducing mesenchymal lineage specificity in human pluripotent stem cell-derived NCCs upon complete ablation of Tsc2 expression (Delaney et al., 2020). Similarly, Tsc1−/− NCCs were observed to drive the development of sclerotic craniofacial bone lesions in a floxed Tsc1−/−/Mpz mouse model (Fang et al., 2015). Furthermore, concomitant increase in tumor volume and number with increases in the proportion of tdTomato+ NCCs identified in this study could indicate that more Tsc2+/− NCCs initiate increased interstitial paracrine signaling that thus co-opt a greater number of host cells expanding proliferation and secretion of cystic volume. More tdTomato+ NCCs engaging in self-renewal proliferative processes can account for large numbers of tumors in the same or varied organs which altogether index more aggressive tumorigenic phenotypes.

Mutations in the Tsc1 and predominantly the Tsc2 gene loci give rise to constitutive mTOR kinase activity and unregulated cell growth and metabolism causing TS tumors (El-Hashemite et al., 2003; Giannikou et al., 2016; Inoki et al., 2003; Kenerson et al., 2007). However, in studies conducted by our group and others (Hartman et al., 2009; Higa et al., 2009; Lee et al., 2010; Li et al., 2014), several mTOR-independent pathogenic mechanisms for TS have been demonstrated in diseased tissues haploinsufficient at the Tsc2 locus. Such exemplary mTOR-independent signaling was observed in our studies demonstrating the requirement of the misexpression of DNA transcription factor High-Mobility Group (HmgA2) in mesenchymal and...
Figure 4. Visualizing neural crest lineage cells in Tsc2+/− mouse renal tumors
(A–D) Representative tdTomato and merged tdTomato/DAPI images of immunohistochemical slices (4 μM thickness) of renal tumors showing punctate singlets and colonies of tdTomato+ neural crest cell populations obtained in 6-month-old (A and B) and 12-month-old (C and D) Tsc2+/− Mpz(Cre)Tdτfl/fl mice viewed using an excitation filter of 540/45 nm in a confocal microscope.
(E–H) Comparative image panel of renal tissue from wild-type 12-month-old mice. Double immunolabeling of renal tumor slices obtained from 16-month-old Tsc2+/− Mpz(Cre)Tdτfl/fl mice reveal tandem endogenous expression of Mpz-driven tdTomato red fluorescent protein (F), Alexa Fluor 488-labeled CD57 neural crest marker expression (G), and tdTomato/CD57/DAPI merged images (H) confirming neural crest identity of these cells. Confocal and fluorescence imaging was performed using N = 3 slides; 2 sections/slide to visualize each renal tumor/tissue. Scale bar represents 50 μm. See also Figures S1 D and S1 E for fluorescent imaging of immunohistochemical slices of hepatic lesions of Tsc2+/− Mpz(Cre)/Tdτfl/fl mice showing punctate tdTomato+ NCCs.

epithelial tumors, and the concomitant expression of upstream and downstream targets of Hmga2 such as insulin-like growth factor 2 mRNA-binding protein 2 (lgf2bp2), let-7, and lin28 in Tsc2+/− mouse tumors (Berner et al., 1997; D’Armiento et al., 2007; D’Armiento et al., 2016; Hunter et al., 2002; Kazmierczak et al., 1996; Tallini et al., 2000). This implicates an active Hmga2 pathway inducing tumorigenesis in these
study models. Given our findings and above that TS tumors are phenotypically mesenchymal and originate from the neural crest and the exclusive expression of Hmga2 in embryonic undifferentiated mesenchyme (Chiappetta et al., 1996; Hock et al., 2006), Hmga2 misexpression could potentially define the ability of Tsc2+/- NCCs to form mesenchymal tumors. Furthermore, it is evident that the pathogenic cells of TS possess an enduring stemness characteristic. HMGA2 as a stemness gene has been implicated in NCC fate specification (Macri et al., 2016) and self-renewal of NCC derivative neural stem cells (Nishino et al., 2008), regulating these developmental events in a manner similar to the gene’s effect in propagating mammalian tumorigenesis (Macri et al., 2016; Nishino et al., 2008). NCC progenitors differentiate into ecto-mesenchymal tissue derivatives following EMT during embryogenesis (Duband, 2000; Duband et al., 1995). Given our prior determination of the necessity for expression of Hmga2 for mesenchymal tumorigenesis in Tsc2+/- mice, the gene’s expression in 100% of human and mice TS tumors, and its influence in increasing the number of renal tumors (D’Armento et al., 2016), Hmga2 could be acting downstream of NCC delamination and Tsc2 mutational events to determine the tumorigenic potential and destiny of migratory NCCs causative for TS neoplasms.

These studies provide evidence for a neural crest origin for tumorigenic cells in lesions from Tsc2+/- mouse models and suggest that a treatment approach specifically targeting neural crest progenitor cells could potentially provide an alternative to mTOR inhibitors as treatment for TS. While mTOR inhibitors remain cytostatic to TS tumorigenic cells (Henske and McCormack, 2012), inhibitors to neural crest markers such as AP2a expressed in renal tumors examined in this study have the potential to inhibit DNA transcription and stymy tumor cell growth leading to an alternative or adjunctive therapeutic agent for TS.

Limitations of the study
Given the multi-systemic occurrence of neoplasms in patients with TS as well as in the Tsc2+/- reporter mouse model, it would have been prudent to distinguish the genomic characteristic of individual tumors assessed from the same or different diseased mouse organ(s). However, the low proportion and viability of flow-sorted tdTomato+ renal tumor cells resolved in this study limited our ability to perform downstream biochemical analysis of excised tumors, necessitating our pooling of tumors for analysis. This was not an ideal methodology for comprehensive testing of our hypothesis that Tsc2+/- mouse renal tumors were neurocristopathic because the characteristic phenotype of these different tumors is thus not known. Future

Figure 5. Neural crest marker expression in Tsc2+/- mouse renal tumors
(A) RNA extracts of Tsc2+/- Mpo(Cre)TdTfl/fl mice kidney parenchyma and Tsc2+/- Mpo(Cre)TdTfl/fl mice renal tumors from 16-month-old mice analyzed by RT-qPCR for neural crest marker expression depict significantly increased expression of transcription factor activating protein—Tfap2a (p = 4.40 × 10^-3**) and CD57 (β-1,3-glucuronyltransferase (B3GAT1)) (p = 0.05*). (B) There was no statistically significant difference in Tsc2 gene expression state between wild-type kidney tissues and renal tumors in Tsc2+/- mice (p = 0.0824). RT-qPCR experiments were performed using triplicate biological samples applied in PCR plates in quadruplicates.
single-cell RNA sequencing studies of dissociated Tsc2+/− mouse renal tumors will overcome this limitation. Additionally, the inability of the majority of Tsc2+/− mice to spontaneously develop pulmonary tumors, as well as other regularly occurring tumors and phenotypes of patients with TS, limits its appropriateness as a model of TS and specifically LAM, central to our laboratory investigations. The short life span of the Mpz-driven tdTomato expression in renal tumors limits our ability for prolonged microscopic examination of renal tumor slices by confocal or fluorescence microscopy and employing anti-tdTomato antibodies did not diminish the quenching of the fluorescent signal.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Mouse genetic studies
- METHOD DETAILS
  - Tumor tracking protocols
  - Mouse renal tumor processing and flow cytometry
  - Neural crest cell culture
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102684.

ACKNOWLEDGMENTS
We thank Tina Zelonina for assistance in mouse breeding and genotyping, tumor excision, and volume measurements. We also thank Christopher Damoci for his technical expertise during small animal imaging and data analysis. This study was supported by grants from the Center for LAM and Rare Lung Diseases at Columbia University. J.D is supported by NIH RO1-HL086936 and Congressionally Directed Medical Research Programs (CDMRP) grant (TS170057). U.U is supported by Congressionally Directed Medical Research Programs (CDMRP) grant (TS170057). M.G is supported by NIH KO8 (HL126071).

AUTHOR CONTRIBUTIONS
Conceptualization, U.U., T.S., K.C., and J.D.; methodology, U.U., T.S., M.G., and J.D.; investigation, U.U.; formal analysis, U.U.; resources, M.G. and J.D.; writing – original draft, U.U., T.S., and J.D.; writing – review & editing, U.U., M.G., K.C., and J.D.; visualization, U.U. and J.D.; supervision, K.C. and J.D.; funding acquisition, M.G. and J.D.

DECLARATION OF INTERESTS
The authors declare no competing interests.

INCLUSION AND DIVERSITY
We worked to ensure sex balance in the selection of non-human subjects. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.

Received: December 15, 2020
Revised: April 20, 2021
Accepted: May 31, 2021
Published: July 23, 2021
REFERENCES

Achilleos, A., and Trainor, P.A. (2012). Neural crest stem cells: discovery, properties and potential for therapy. Cell Res. 22, 288–304.

Au - Gonzalez Malagon, S.G., Au - Dobson, L., Au - Muñoz, A.M.L., Au - Dawson, M., Au - Barrell, W., Au - Marangos, P., Au - Krause, M., and Au - Liu, K.J. (2019). Dissection, culture and analysis of primary cranial neural crest cells from mouse for the study of neural crest cell delamination and migration. JoVE, e60051.

Badri, K.R., Gao, L., Hyek, E., Schuger, N., Schuger, L., Qin, W., Chekaluk, Y., Kwiatkowski, D.J., and Zhe, X. (2013). Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 187, 663–665.

Baggiolini, A., Varum, S., Mateos, J.M., Bettosini, D.J., and Zhe, X. (2013). Exonic mutations of the gene for an architectural transcription factor, HMGA2, occur at a high frequency in lymphangioleiomyomatosis. N. Engl. J. Med. 368, 6085–6090.

Chiappetta, G., Avantaggiato, V., Visconti, R., Fedele, M., Bartatta, S., and Pelicci, P.G. (1996). High level expression of the HMGI(Y) gene during embryonic development. Oncogene 13, 2439–2446.

Clements, D., Dongre, A., Krymskaya, V.P., and Johnson, S.R. (2015). Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis. PLoS One 10, e0126025.

Clements, D., Miller, S., and Johnson, S.R. (2020). Pulmonary lymphangioleiomyomatosis originates in the pleural mesothelial cell population. Med. Hypotheses 141, 109703.

D’Armento, J., Imai, K., Schiltz, J., Kolesnikova, P., Sagawa, K., Shinozuka, Y., et al. (2010). Identification of the benign mesenchymal tumour gene HMG2A in lymphangioleiomyomatosis. Cancer Res. 70, 1902–1909.

D’Armento, J., Shiomi, T., Marks, S., Geraghty, P., Sankararshan, D., and Chada, K. (2016). Mesenchymal precursor generation driven by TSC2 haploinsufficiency requires HMG2A and is independent of mTOR pathway activation. Cancer Res. 76, 844–854.

Dabola, S.L., Jozwiak, S., Franz, D.N., Roberts, P.S., Nieto, A., Chung, J., Choy, Y.S., Reeve, M.P., Thiele, E., Egelhoff, J.C., et al. (2001). Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2 compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68, 64–80.

Davies, D.M., de Vries, P.J., Johnson, S.R., McCartney, D.L., Cox, J.A., Serra, A.L., Watson, P.C., Howe, C.J., Doyle, T., Pointon, K., et al. (2011). Sirolimus therapy for angiomyolipoma in tuberin tumours: a pilot study. Clin. Cancer Res. 17, 4071–4081.

de Vries, P.J., Whittemore, V.H., Lecleci, L., Byars, A.W., Dunn, D., Ess, K.C., Hook, D., King, B.H., Sahin, M., and Janssen, L. (2015). Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist: Pediatr. Neurol. 52, 25–35.

Delaney, S.P., Caudill, M., Petrobon, A., Yockelli, L., D’Armiento, J., Doré, C., Wang, T.T., Doyon, V.C., Raymond, A., Patten, D.A., and Kristof, A.S., et al. (2020). Human pluripotent stem cell modeling of tuberous sclerosis complex reveals tissue-specific therapeutic vulnerabilities. bioRxiv, 683359.

Delaney, S.P., Julian, L.M., and Stanford, W.L. (2014). The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis. Front. Cell Dev. Biol. 2, 69.

Dixon, B.P., Hubbert, J.C., and Bissler, J.J. (2011). Tuberous sclerosis complex renal disease. Nephron Exp. Nephrol. 118, e15–e20.

Duband, J.L. (2000-2013). Neural crest delamination and migration: integrating regulations of cell interactions and fate. In Madame Curie Bioscience Database (Landes Bioscience), pp. 1–42.

Duband, J.L., Manier, F., Delannet, M., and Newgreen, D. (1995). Epithelium-mesenchyme transition during neural crest development. Acta Anat. (Basel) 154, 63–78.

Dupin, E., and Coelho-Aguiar, J.M. (2013). Isolation and differentiation properties of neural crest stem cells. Cytometry. A 83, 38–47.

El-Hashemite, N., Zhang, H., Henske, E.P., and Kwiakowski, D.J. (2003). Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 361, 1346–1349.

Fang, F., Sun, S., Wang, L., Guan, J.L., Giovanni, M., Zhu, Y., and Liu, F. (2015). Neural crest-specific TSC1 deletion in mice leads to sclerotic craniofacial bone lesion. J. Bone Miner Res. 30, 1195–1205.

Faustino-Rocha, A., Oliveira, P.A., Pinho-Oliveira, J., Teixeira-Guedes, C., Soares-Maia, R., da Costa, R.G., Colaco, B., Pires, M.J., Colaç, J., Ferreira, R., et al. (2013). Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab. Anim. 42, 217–224.

Feliciano, D.M. (2020). The neurodevelopmental pathogenesis of tuberous sclerosis complex (TSC). Front. Neurol. 11, 59.

Feliciano, D.M., Quon, J.L., Su, T., Taylor, M.M., and Bordey, A. (2012). Postnatal neurogenesis generates heterotopias, oligfatory microcircuits and cortical infiltration following single-cell Tsc1 deletion. Hum. Mol. Genet. 21, 799–810.

Ferrans, V.J., Yu, Z.X., Nelson, W.K., Valencia, J.C., Tatsuguchi, A., Avila, N.A., Remenschnig, W., Matsui, K., Travis, W.D., and Moss, J. (2000). Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J. Nippon Med. Sch. 67, 311–329.

Festing, M.F. (2006). Design and statistical methods in studies using animal models of development. ILAR J. 47, 3–14.

Festing, M.F., and Altman, D.G. (2002). Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 43, 244–258.

Franz, D.N., Belousova, E., Srapragana, S., Bebin, E.M., Frost, M., Kuperman, R., Witt, O., Kohnen, M.H., Flaimin, J.R., Wu, J.Y., et al. (2013). Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381, 125–132.
Antibodies that recognize P0 mark a neural crest-derived cell type that displays community effects in response to TGF-beta family factors. Development 126, 3781–3794.

Hartman, T.R., Liu, D., Watanabe, J.T., and Somsen, G. (1999). P0 and PMP22 mark a multipotent neural crest-derived cell type that displays community effects in response to TGF-beta family factors. Development 126, 3781–3794.

Henske, E.P.; Jozwiak, S., Kingswood, J.C., Bolton, P., Crawford, P., Harland, C., and Walker, C.L. (2002). Aberrant expression of retinaldehyde dehydrogenase 1A, 1B, and 1C in neural tube defects. J. Comp. Neurol. 447, 227–236.

Higuchi, T., Kojima, Y., and Suzuki, I. (2014). P0, a neural crest cell marker, is expressed in normal and aberrant mouse retinal development. Dev. Dyn. 243, 885–893.

Higuchi, T., Kojima, Y., and Suzuki, I. (2014). P0, a neural crest cell marker, is expressed in normal and aberrant mouse retinal development. Dev. Dyn. 243, 885–893.

Hok, R., Witte, F., Brocher, J., and Somsen, G. (2005). Expression of HMGAM2, a neural crest cell marker, is maintained in the developing retina and its absence causes retinal degeneration. Dev. Dyn. 234, 401–412.

Hollinger, G.W., Zhang, Y., and Berliner, J.L. (2013). Conditional deletion of the mTOR inhibitor TSC2 in the retina results in degeneration of photoreceptor and Müller glial cells. Proc. Natl. Acad. Sci. U. S. A. 110, 1206–1211.

Hong, H., Li, Y., and Koike, S. (2019). P0 expression in neural crest and retinal precursor cells and its role in retinal development. Invest. Ophthalmol. Vis. Sci. 60, 117–126.

Hoshi, K., Ohtsuka, C., and Ueno, T. (2012). Immunohistochemical study of P0 expression in the developing retina and its role in retinal development. Invest. Ophthalmol. Vis. Sci. 53, 5922–5929.

Horie, K., Sato, T., and Kuroda, Y. (2015). P0 expression in the developing retina and its role in retinal development. Invest. Ophthalmol. Vis. Sci. 56, 111–112.

Horiuchi, T., Horiuchi, M., and Horiuchi, S. (2016). P0 expression in the developing retina and its role in retinal development. Invest. Ophthalmol. Vis. Sci. 57, 503–511.
Oncotarget syndromes: altered genomic transcription in (2017). Haploinsufficiency in tumor predisposition
30
lymphangioleiomyomatosis cells. Crit. Rev. Biol. 164, 409–419.

Pacheco-Rodriguez, G., and Moss, J. (2010). The role of chemokines in migration of metastatic-like
lymphangiogenic tumors. J. Clin. Invest. 126, 2635–2640.

Peri, S., Caretti, E., Tricarico, R., Devarajan, K., Cheung, M., Sementino, E., Menges, C.W., Nicolas, E., Vanderveen, L.A., Howard, S., et al. (2017). Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget 8, 17628–17642.

Faltzgraff, E.R., Mundell, N.A., and Labosky, P.A. (2012). Isolation and culture of neural crest cells from embryonic murine neural tube. J. Vis. Exp. e4134.

Qin, W., Bajaj, V., Malinowska, I., Lu, X., MacConall, L., Wu, C.L., and Kwiatkowski, D.J. (2011). Angiomyolipoma have common mutations in TSC2 but no other common genetic events. PLoS One 6, e24919.

Rakowski, S.K., Winterkorn, E.B., Paul, E., Steele, D.J., Halpern, E.F., and Thiele, E.A. (2006). Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 70, 1777–1782.

Ren, S., Luo, Y., Chen, H., Warburton, D., Lam, H.C., Wang, L.I., Chen, P., Henske, E.P., and Shi, W. (2016). Inactivation of Tsc2 in mesoderm-derived cells causes polycystic kidney lesions and impairs lung alveolarization. Am. J. Pathol. 188, 3261–3272.

Santrock, O., Nelliit, M., Goebbels, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., and van den Ouwehand, A. (2005). Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur. J. Hum. Genet. 13, 731–741.

Säpi, J., Kovács, L., Drechsler, D.A., Kocsis, P., Gajári, D., and Sapi, Z. (2015). Tumor volume estimation and quasi-continuous administration for most effective bevacizumab therapy. PLoS One 10, e0142190.

Sato, T., Seyama, K., Fuji, H., Maruyama, H., Setoguchi, Y., Ikawaki, S., Fukuchi, Y., and Hino, O. (2002). Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J. Hum. Genet. 47, 20–28.

Serbedzija, G.N., Bronner-Fraser, M., and Fraser, S.E. (1992). Vital dye analysis of cranial neural crest cell migration in the mouse embryo. Development 116, 297.

Siroky, B.J., Yin, H., and Bissler, J.J. (2011). Clinical and molecular insights into tuberous sclerosis complex renal disease. Pediatr. Nephrol. 26, 839–852.

Smolarek, T.A., Wessner, L.L., McCormack, F.X., Mylet, J.C., Menon, A.G., and Henske, E.P. (1999). Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomylipomas and lymph nodes from women with lymphangioleiomyomatosis. Am. J. Hum. Genet. 62, 810–815.

Sowa, Y., Imura, T., Numajiri, T., Takeda, K., Mabuchi, Y., Matsuzaki, Y., and Nishino, K. (2013). Adipose stromal cells contain phenotypically distinct adipogenic progenitors derived from neural crest. PLoS One 8, e84206.

Tallini, G., Vanni, R., Manfioletti, G., Kazmierzak, B., Faas, G., Pauwels, P., Bullerdiek, J., Gianotti, V., Van Den Bergh, H., and Dal Cin, P. (2000). HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab. Invest. 80, 359–369.

Tam, R.Y., Yockell-Lelievre, J., Smith, L.J., Julian, L.M., Baker, A.E.G., Choey, C., Hasim, M.S., Dimitroulakos, J., Stanford, W.L., and Shoichet, M.S. (2019). Rationally designed 3D hydrogels model invasive lung diseases enabling high-content drug screening. Adv. Mater. 31, e1806214.

Taveira-DaSilva, A.M., and Moss, J. (2015). Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clin. Epidemiol. 7, 249–257.

Tyburczy, M.E., Dies, K.A., Glass, J., Camposano, S., Chekaluk, Y., Thornor, A.R., Lin, L., Krueger, D., Franz, D.N., Thiele, E.A., et al. (2015). Mosaic and intronic mutations in TSC1/TSC2 explain the majority of TSC patients with No mutation identified by conventional testing. PLoS Genet. 11, e1005637.

Van Sluyters, R.C., Ballinger, B., Bayne, K., Cunningham, C., Degeyse, A.-D., Dubner, R., Evans, H., Gdowski, M.J., Knight, R., Mench, J., et al. (2003). Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (National Academies Press (US)).

Wuidart, A., Ousset, M., Rulands, S., Simons, B.D., Van Keymeulen, A., and Blanpain, C. (2016). Quantitative lineage tracing strategies to resolve multipotency in tissue-specific stem cells. Genes Dev. 30, 1261–1277.

Yamachi, Y., Abe, K., Mantani, A., Hitoshi, Y., Suzuki, M., Osuzu, F., Kuratani, S., and Yamamura, K. (1999). A novel transgenic technique that allows specific marking of the neural crest cell lineage in mice. Dev. Biol. 212, 191–203.

Yao, J., Taveira-DaSilva, A.M., Jones, A.M., Julien-Williams, P., Stylianou, M., and Moss, J. (2014). Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 190, 1273–1282.

Yu, J., and Henske, E.P. (2010). mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the “perfect storm” of pro-metastatic factors in LAM pathogenesis. Lymphat Res. Biol. 8, 43–49.

Yu, J.J., Robb, V.A., Morrison, T.A., Ariazi, E.A., Karbowicz, M., Aastrindis, A., Wang, C., Hernandez-Cuebas, L., Seeholzer, L.F., Nicolas, E., et al. (2009). Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc. Natl. Acad. Sci. U S A 106, 2635–2640.
## STARMETHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Mouse monoclonal anti-CD57 | Santa Cruz Biotechnology | Cat# sc-6261; RRID: AB_627130 |
| Donkey anti-mouse IgG Alexa Fluor 488 | Thermo Fisher Scientific | Cat# A21202; RRID:AB_141607 |
| **Chemicals, Peptides, and Recombinant Proteins** | | |
| DMEM/F12 (1:1) | Thermo Fisher Scientific | Cat# 11320033 |
| EmbryoMax DMEM - High Glucose, Low Bicarbonate without sodium pyruvate | Millipore Sigma | Cat# SLM-220-M |
| ESGRO Leukemia Inhibitory Factor (LIF) | Millipore Sigma | Cat# ESG1106 |
| Fetal bovine serum (FBS) | GE Healthcare Biosciences | Cat# SH30071.03 |
| EmbryoMax ES Fetal Bovine Serum | Millipore Sigma | Cat# ES-009-C |
| Penicillin-Streptomycin | Thermo Fisher Scientific | Cat#15140122 |
| Collagenase I | Worthington Biochemicals | Cat# L5004196 |
| DNase I | Millipore Sigma | Cat# 4716728001 |
| Elastase | Worthington Biochemicals | Cat# L5002294 |
| Normal Donkey Serum | Sigma-Aldrich | Cat# D9663 |
| Sodium Azide | Sigma-Aldrich | Cat# 52002 |
| DRAQ5 | Bioreagents | Cat# 424101 |
| Isoflurane | Henry Schein | Cat# 1311758 |
| RBC Lysis Buffer | Santa Cruz Biotechnology | Cat# sc-296258 |
| Sytox Green Nucleic Acid Stain | Thermo Fisher Scientific | Cat# 57020 |
| DAPI | Thermofisher Scientific | Cat# D1306 |
| β-mercaptoethanol | Thermofisher Scientific | Cat# O3446I |
| Sodium Pyruvate | Thermofisher Scientific | Cat# 11-360-070 |
| L-Glutamine | Millipore Sigma | Cat# G7513 |
| Minimum essential media nonessential amino acids (MEM NEAA) | Thermofisher Scientific | Cat# 11095080 |
| Basic fibroblast growth factor (bFGF) | Millipore Sigma | Cat# GF003 |
| Triton X-100 | Thermofisher Scientific | Cat# BP151-500 |
| Bovine Serum Albumin | Millipore Sigma | Cat# A8412 |
| Normal Donkey Serum | Millipore Sigma | Cat# D9663 |
| Prolong Diamond Anti-fade Mountant with DAPI | Thermofisher Scientific | Cat# P36971 |
| **Critical Commercial Assays** | | |
| RNeasy Mini Kit | Qiagen Inc. | Cat# 74106 |
| High-Capacity cDNA Reverse Transcription Kit | Thermo Fisher Scientific | Cat# 4368813 |
| QIAamp DNA Mini Kit | Qiagen Inc. | Cat# 51304 |

**Deposited data**

- Original data for Figures 2J–2S: Mendeley [https://doi.org/10.17632/tsjk7wm5s8.1#file-7f9e656d-e11b-4ab4-be87-6e99139b3ab9](https://doi.org/10.17632/tsjk7wm5s8.1#file-7f9e656d-e11b-4ab4-be87-6e99139b3ab9)

**Experimental Models: Cell Lines**

- STO Feeder Cell Line: ATCC | Cat# CRL-1503 RRID:CVCL_3420

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jeanine D’Armiento (jmd12@cumc.columbia.edu).

Materials availability
This study did not generate new unique reagents.

Data and code availability
Original data for Figures 3A–3J in the paper is available (Mendeley Data DOI: https://doi.org/10.17632/tsjk7wm5s8.1#file-7f9e656d-e11b-4ab4-be87-6e99139b3ab9)

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mouse genetic studies
Animal experimentation was performed according to the Declaration of Helsinki convention for the use and care of animals and approved by the Institutional Animal Care and Use Committee (IACUC) at Columbia University Medical Center under protocol #AC-AAAR3401. The tuberous sclerosis Tsc2+/- transgenic...
reporter mice was generated by crossing floxed B6.Cg-Gt(Rosa)26Sor<sup>tm1.CAG-tdTomato</sup>Hze/J reporter mice (JAX #007909, RRID:IMSR_JAX:007909) (female, N = 10 animals, 10 weeks old) with transgenic B6N.FVB-Tg(Mpz-Cre)26Mes/J mice (JAX #017927, RRID:IMSR_JAX:017927) (male, N = 10 animals; 10 weeks old) encoding a cell adhesion molecule myelin protein zero (P<sub>0</sub>) promoter driving expression of Cre recombinase specifically in neural crest and Schwann cells (Kaku et al., 2012; Sowa et al., 2013; Yamauchi et al., 1999). These mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained on a C57BL/6J background. B6. Cg-Mpz(Cre)<sup>tm1.CAG-tdTomato</sup> progeny (male/female, N = 8 animals), obtained after backcrosses (N > 5) to R26 mice, were then bred with tuberous sclerosis Tsc2<sup>+/−</sup> mice (RRID:IMSR_JAX:004686) (male/female, 10 weeks old, N = 10 animals) containing a neo-cassette targeted disruption of the second coding exon in the Tsc2 gene (Onda et al., 1999). Following F1 hybrid crosses of Tsc2<sup>+/−</sup>/Mpz(Cre)/TdT<sup>fl/fl</sup> mice and genotyping analysis, Tsc2<sup>−/−</sup>/Mpz(Cre)/TdT<sup>fl/fl</sup> (male/female, N = 22 animals), Tsc2<sup>−/−</sup>/Mpz(Cre)/TdT<sup>fl/−</sup> (male/female, N = 13 animals), Tsc2<sup>−/−</sup>/Mpz(Cre)/TdT<sup>−/−</sup> (male/female, N = 15 animals), and control Tsc2<sup>−/−</sup>/Mpz(Cre)/TdT<sup>−/−</sup> (male/female, N = 12 animals) mice development was monitored for 16 months and sacrificed for experiments. A schematic of genetic crosses involved in the development of this mouse model is displayed in Figure 1A. Tracking of spontaneous renal tumor development in all mouse genotypes commenced at 2 months of age, using tumor tracking protocols described below.

All mouse genotypes were confirmed by Southern hybridization of genomic DNA prepared from tail biopsies. Mouse sample sizes for each genotype utilized in this study are adequate to measure Tsc2<sup>−/−</sup>-induced tumorigenesis detectable by tdTomato expression of neural crest cells expressing the Cre recombinase under the control of Mpz promoter, in comparison to mouse progeny wildtype for Tsc2 and non-transgenic R26R mice. Given the time required for tumors to develop in the Tsc2<sup>−/−</sup> mice, the 80-90% rate of spontaneous tumorigenesis in the kidneys and liver, the number of pups per litter yield for each genotype, the isogenicity of strains specified for genetic crosses, and comparative studies between mouse genotypes, such an assumption can be made for the four genotypes being compared, using mouse attrition rate of 8%, statistical power of 0.8 with double-sided α error of 0.05 (Festing and Altman, 2002). Blinding was assured in this study because mouse genetic crosses to obtain desired genotypes, assessments of resulting phenotypes, and selection of mice for comparative imaging studies, were all performed by an independent laboratory technician without knowledge of the hypothesis being tested. Genotyping results determined assignments of mouse pups to the different genetic backgrounds. Inbred littersmates were used in each mouse genotype category and mice were age- and sex-matched for each group. Mouse littersmateres were also selected for genetic crosses at random. All attempts at replication in this study yielded successful reproducibility 90% of the time. All tumor tracking, measurement and excision experiments were repeated 2-3 times on different days per age group.

**METHOD DETAILS**

**Tumor tracking protocols**

Non-invasive monitoring of renal tumor development in the TS reporter mouse was performed by sequential IVIS spectral imaging, small animal ultrasound and confirmatory magnetic resonance imaging (MRI) as described below. Tumor monitoring began at 2 months of age with biweekly intervals up to 16 months of age. All animal imaging, data acquisition and analysis was performed at the Oncology and Precision Therapeutics and Imaging Core (OPTIC) of the Columbia University Medical Center in accordance with the guidance of the Institutional Animal Care and Use Committee.

**Biofluorescence imaging.** Mice were anesthetized with inhaled 2.5% isoflurane (Cat# 1311758, IsoTheisa™, Henry Schein, Melville, NY), and the abdomen of the animal was fully shaved using electric shears and depilatory cream (Nair™ Church & Dwight Co. Trenton, NJ). Mice were then positioned supine on the warming stage of the In Vivo Imaging System (IVIS) Spectrum (Perkin Elmer, Santa Clara, CA) directly facing the camera sensor to monitor heart rate and body temperature, and capture fluorescence images. In vivo imaging system parameters were determined using standard optimization protocols with spectral unmixing. Each IVIS imaging procedure was completed within 5-10 minutes; animals were monitored until fully recovered from anesthesia. Fluorescence images were analyzed and total radiant efficiency (photons/s/[μW/cm²]) calculated using the Living Image version 4.5 software (Perkin Elmer, Santa Clara, CA).

**High frequency ultrasound imaging.** Animals were anesthetized with 2.5% isoflurane (IsoTheisa™, Henry Schein, Melville, NY) and placed on an electric heating pad to prevent hypothermia; abdominal hair was removed as described. Animals were positioned supine to monitor heart rate and body temperature.
Images of renal sagittal sections were obtained using the VisualSonics Vevo® 2100 Imaging System with 550D scan head (FUJIFILM VisualSonics Inc., Toronto, ON) at 55 megahertz. The 3-D Mode was used for advanced data acquisition and analysis, with virtual sections obtained in all directions (x-, y-, z- and other plane variations). Each ultrasound was completed within 10–15 minutes; animals were monitored until fully recovered from anesthesia. Ultrasound images were analyzed using the VEVO Lab 4.1 software provided by VisualSonics (Toronto, ON).

**Magnetic Resonance Imaging (MRI).** The MRI examination of the abdomen of the mice was performed to confirm findings of ultrasound scans in some experimental mice. MRI was performed with a 9.4 Tesla animal scanner (Bruker BioSpin, Germany). Animals were anesthetized by inhalation of isoflurane (IsoThesia™, Henry Schein, Melville, NY) (3% induction and 1-2% maintenance) and were kept homeothermic by a water-circulating system to keep the MRI bed at 37°C. A Rapid Imaging with Refocused Echoes sequence was used to acquire multi-slice images in the long axis of both kidneys by using the following parameters: TR/TE = 2600/30 ms, averages = 4, RARE factor = 8, matrix = 256x256, field of view = 40x40 mm², slice thickness = 0.5 mm. MRI images were analyzed utilizing the Paravision 6.0 software from Bruker BioSpin.

**Mouse renal tumor processing and flow cytometry**

Individual renal tumor length and width per kidney pair per mice were measured using digital calipers following mice sacrifice. Tumor volumes were estimated using the formula: 

\[ \text{Volume} = \frac{\text{Width}^2 \times \text{Length}}{2} \]

(Faustino-Rocha et al., 2013; Szapi et al., 2015). Renal tumor and tissues biopsied from Tsc2\(^{+/+}\)/Mpz(Cre)/TdT\(^{fl/fl}\), Tsc2\(^{+/+}\)/Mpz(Cre)/TdT\(^{+/+}\), Tsc2\(^{-/-}\)/Mpz(Cre)/TdT\(^{fl/fl}\), and control Tsc2\(^{+/+}\)/Mpz(Cre)/TdT\(^{+/+}\) mice at 4, 6, 12, and 16 months were pooled by age group and digested into single cell suspension (Neelisetty et al., 2015). Samples were minced in DMEM-F12 media supplemented with 2% fetal bovine serum (FBS) (#SH30071.03, Hyclone, GE Healthcare Biosciences, Piscataway, NJ) using fine sterile razors and digested with a cocktail of collagenase I (170mg/L, Cat# LS004196, Worthington Biochemical, Lakewood, NJ), DNase I (0.33 U/ml; Cat# 4716728001, Millipore Biosciences, Piscataway, NJ) using fine sterile razors and digested with a cocktail of collagenase I (170mg/L, Cat# LS004196, Worthington Biochemical, Lakewood, NJ) in a shaker at a speed of 85rpm at 37°C for 45 mins. Tissue particles were vigorously triturated and re-incubated in the same conditions for another 30 mins then passed through 100µm, 70µm, and 40µm cell strainers sequentially. Cell suspensions were centrifuged for 5 min at 300 x g at room temperature, supernatant aspirated, and the erythrocytes lysed using 1x RBC lysis buffer (Cat# sc-296258, Santa Cruz Biotechnology, Dallas, TX) for 10 mins. Following subsequent centrifugation for 5 min at 300 x g, cell pellets were resuspended in PBS containing 2% FBS and DAPI (Cat# D1306, Thermofisher Scientific, Grand Island, NY) or Sytox green viability dye (Cat# 424101, BioLegend, San Diego, CA) in some experiments to distinguish viable cells. Flow cytometry was performed using a BD FACS Aria II (Becton Dickinson, Franklin Lakes, NJ) at the Columbia Stem Cell Initiative (CSCI) Flow Cytometry Core Facility and cells were sorted into tubes pre-incubated with DMEM-F12 containing 2% FBS. Single cells were sequentially selected on FSC-A/SSC-A and FSC-A/FSC-H dot plots and band-pass filters 586/15, 530/30, 450/50, or 715/50 were used to acquire tdTomato and viability dye signals. Tubes with unsorted cells were used to set compensation and at least 50,000 events were collected for each tumor or tissue sample sorted into tdTomato\(^{+/+}\) vs tdTomato\(^{-/-}\) fractions per experiment. Data analysis was performed using FlowJo 10.7.1 (BD Biosciences, Franklin Lakes, NJ) or FCS Express 7 Plus (De Novo Software, Glendale, CA).

**Neural crest cell culture**

Cranial (CNCC) and trunk (TNCC) neural crest cells were used as positive comparative controls for flow cytometry and RT-qPCR experiments. These tissues were obtained from 9.5dpc Tsc2\(^{-/-}\)/Mpz(Cre)/TdT\(^{fl/fl}\) fetal mice excavated from pregnant dam. Isolation of CNCCs was performed by cutting a region between head fold and the anterior tip of the otic placode of mouse embryos (Au - Gonzalez Malagon et al., 2019) under mice excavated from pregnant dam. Isolation of CNCCs was performed by cutting a region between head fold and the anterior tip of the otic placode of mouse embryos (Au - Gonzalez Malagon et al., 2019). Tissue dissected were placed in the center of sterile matrigel-coated petri dishes containing neural crest media and incubated at 37°C in 5% CO2 to allow for migration of NCCs away from the neural tube. NCC media was conditioned using STO feeder cells (mouse embryonic fibroblasts) (ATCC Cat# CRL-1503, RRID:CVCL_3420) grown overnight in Dulbecco’s modified Eagle’s medium (DMEM, 4500mg/L glucose) (Cat# SLM-220-M, Millipore Sigma, St. Louis, MO) containing 15% fetal bovine serum (FBS) (Cat# ES-009-C, Millipore Sigma, St. Louis, MO), 0.1mM minimum essential media nonessential amino acids (MEM NEAA 100X) (Cat# 11095080), 1 mM sodium pyruvate (Cat# 11-360-070, Thermofisher...
Scientific, Grand Island, NY), 55 μM β-mercaptoethanol (Cat# O3446L-100, Thermofisher Scientific, Grand Island, NY), 100 units/mL penicillin-streptomycin (Cat#15140122, Thermofisher Scientific, Grand Island, NY) and 2 mM L-glutamine (Cat# G7513, Millipore Sigma, St. Louis, MO). Conditioned media was thereafter supplemented with basic fibroblast growth factor (bFGF, 25ng/ml) (Cat# GF003, Millipore Sigma, St. Louis, MO) and leukemia inhibition factor (LIF, 1000U) (Cat# ESG1106, Millipore Sigma, St. Louis, MO). 48hrs after NCC migration from neural tube, explant tissue is removed and NCCs routinely passaged. NCCs were incubated in DAPI viability dyes for 10 mins prior to flow cytometry experiments.

**Immunohistochemistry.** Renal tumor and tissues of differentially aged mice were excised, briefly washed in PBS and immediately fixed in 4% paraformaldehyde (PFA) for 2 hours at room temperature. Renal tumors and tissues are then rinsed in PBS and incubated overnight at 4°C in 30% sucrose to preserve endogenous protein expression (Wuidart et al., 2016). Thereafter, fixed tissues/tumors were immediately embedded in OCT compound, snap-frozen in isopentane mixed with dry ice and kept at -80°C. Embedded tissues were used to obtain 4 μm thick sections at the Molecular Pathology Core Facility at Columbia University Medical Center.

For CD57 (β-1,3-glucuronyltransferase (B3GAT1)) immunolabeling (sc-6261; RRID: AB_627130; Santa Cruz Biotechnologies, Dallas, TX), tissue/tumor slices were blocked and permeabilized for 1 hour at room temperature using a mixture of 0.3% Triton X-100 (Cat# B P151-500, Thermofisher Scientific, Grand Island, NY), bovine serum albumin (BSA) (Cat# 8412, Millipore Sigma, St. Louis, MO) and 10% normal donkey serum (NDS) (Cat# D9663, Millipore Sigma, St. Louis, MO) and incubated overnight at 4°C in anti-CD57 diluted in antibody dilution buffer (1% BSA, 1% NDS, 0.3% Triton X-100, 0.01% sodium azide). Following 1-hr secondary antibody incubation using donkey anti-mouse Alexa Fluor 488 (Cat# A21202, RRID: AB_141607, Thermofisher Scientific, Grand Island, NY), slides were cover-slipped using Prolong Diamond Anti-fade Mountant (Thermofisher Scientific, Grand Island, NY) and visualized using Ti-E Eclipse inverted fluorescent or confocal microscope (Nikon Instruments Inc., Melville, NY). Immunohistochemistry experiments were repeated twice for each aged mice timepoint using N=3 slides per tissue/tumor, 2-3 sections per slide. The use of mouse tissues samples was approved by the IACUC protocol #AC-AAAR3401.

**RT-qPCR and southern blot.** Total RNA was isolated from mouse renal tumors and tissue biopsies excised from all mouse genotypes. RNA isolation was performed using RNeasy Mini Kit (#74106, Qiagen Inc., Valencia, CA). High-quality RNA was ensured by UV spectroscopy and incorporating DNase treatment in the protocol. Reverse transcription was performed using the High-Capacity cDNA Reverse Transcription Kit (#4368813; Applied Biosystems, Thermofisher Scientific, Grand Island, NY, USA) (Qin et al., 2011). Quantification of gene expression was assessed in quadruplicates per biological replicate by reverse transcription qPCR using TaqMan probes with FAM dye labels (Thermofisher Scientific, Grand Island, NY). The ABI 7300 real-time sequence detection system (Applied Biosystems, Thermofisher Scientific, Grand Island, NY) was used along with the GeneAmp 7900 SDS software (Cat# 4350490, Applied Biosystems, Thermofisher Scientific, Grand Island, NY) to convert data into threshold cycle (ΔΔCt) values.

For genotyping studies, DNA was isolated from mice tail snips collected in sterile 1.5ml microcentrifuge tubes by digestion in 50mM Tris, pH 8.0, 100mM ethylenediaminetetraacetic acid (EDTA) (Cat# 17892, Thermofisher Scientific, Grand Island, NY), 0.5% sodium dodecyl sulfate (SDS) (Cat# L3771, Millipore Sigma, St. Louis, MO) and 20mg/ml proteinase K (Cat# AM2548, Thermofisher Scientific, Grand Island, NY). After overnight incubation, a phenol:chloroform (1:1) phase separation was performed, and DNA precipitated from the aqueous layer using a sodium acetate and ethanol mixture. DNA solubilized in TE buffer (10mM Tris, pH 8.0, 1mM EDTA) was further resolved on 1.2-2.7% agarose gel and probe hybridization performed using the following cDNA primer sequences: R26R 5'-AAAGTCGCTCTGAGTTGTTAT-3' (forward) and 5'-GGAGCGGGAGAAATGGATATG-3' (reverse); Mpz transgene 5'-CCACCACCCCTCCATTGCAC-3' (forward) and 5'-ATGTTTAGCTGGCCCAAGATG-3' (reverse); Tsc2 5'-CAACACCACCTCCCTTTGGGAGTT-3' (forward) and 5'-AGACTGCTTGGGGAAAAAGCG-3' (reverse) (Integrated DNA Technologies, Research Triangle Park, NC).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

This investigation was utilized as a pilot study to trace the ontogeny of tumorigenic cells in the Tsc2+/− mice; therefore, the less rigorous equation method and upper confidence limit (UCL) approach was
employed to estimate optimal sample size for mouse groups in this pilot study (Festing, 2006). The time required for tumors to develop in Tsc2+/− mice was considered, as well as the 80-90% rate of spontaneous tumorigenesis in the kidneys, the number of pups per litter yield (~7 pups), the total number of litters per genotype used, the isogeneity of strains specified for genetic crosses, mouse attrition rate of 8%, and statistical power of 0.8 with double-sided α error of 0.05 (Festing and Altman, 2002; Van Sluyters et al., 2003). Sample sizes in experiments are specified in each figure legend, and all data in the text and figures are expressed as mean ± SEM. Statistical tests are appropriately justified and performed using a one-way ANOVA with post-hoc Dunnett tests comparing treatment conditions to controls where applicable.